mapk inhibitor sb202190 Search Results


p38 mapk inhibitor sb202190  (Merck & Co)
90
Merck & Co p38 mapk inhibitor sb202190
In vitro lipopolysaccharide (LPS) and lipoteichoic acid (LTA) stimulation of neonatal and adult whole blood (WB) in the presence of specific inhibitors. Human WB was preincubated with 20 μ M of the <t>p38</t> <t>MAPK</t> inhibitor <t>SB202190,</t> 20 μ M of the ERK1/2 inhibitor U0126, 20 μ M of the JNK inhibitor SP600125, or 20 μ M of the NF- κ B inhibitor BAY11-7082, followed by LPS (100 ng/mL) ((a) and (c)) or LTA (100 μ g/mL) ((b) and (d)) for an additional 4 h. Supernatants were then collected, and IL-6 ((a) and (b)) and TNF- α ((c) and (d)) were analyzed using ELISA. Data are presented as fold difference as compared to untreated controls. Values are expressed as mean ± standard error of mean (SEM). * P < 0.05, control versus inhibitor. # P < 0.05, neonatal versus adult.
P38 Mapk Inhibitor Sb202190, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p38 mapk inhibitor sb202190/product/Merck & Co
Average 90 stars, based on 1 article reviews
p38 mapk inhibitor sb202190 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
sb202190 (p38 mapk inhibitor)  (Nacalai)
90
Nacalai sb202190 (p38 mapk inhibitor)
In vitro lipopolysaccharide (LPS) and lipoteichoic acid (LTA) stimulation of neonatal and adult whole blood (WB) in the presence of specific inhibitors. Human WB was preincubated with 20 μ M of the <t>p38</t> <t>MAPK</t> inhibitor <t>SB202190,</t> 20 μ M of the ERK1/2 inhibitor U0126, 20 μ M of the JNK inhibitor SP600125, or 20 μ M of the NF- κ B inhibitor BAY11-7082, followed by LPS (100 ng/mL) ((a) and (c)) or LTA (100 μ g/mL) ((b) and (d)) for an additional 4 h. Supernatants were then collected, and IL-6 ((a) and (b)) and TNF- α ((c) and (d)) were analyzed using ELISA. Data are presented as fold difference as compared to untreated controls. Values are expressed as mean ± standard error of mean (SEM). * P < 0.05, control versus inhibitor. # P < 0.05, neonatal versus adult.
Sb202190 (P38 Mapk Inhibitor), supplied by Nacalai, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sb202190 (p38 mapk inhibitor)/product/Nacalai
Average 90 stars, based on 1 article reviews
sb202190 (p38 mapk inhibitor) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
p38 mapk inhibitor sb 202190  (Merck & Co)
90
Merck & Co p38 mapk inhibitor sb 202190
(A, B) Calu-3 cells were treated with flagellin (200 ng/ml) in the presence (10 μM) or absence of inhibitors of ERK or <t>p38</t> <t>MAPK</t> (A), or NF-κB (B) for 24 h. Untreated and DMSO-treated cells served as controls. mRNA expression levels of TMPRSS2 and IL-6 were analyzed at 24 h post-treatment by RT–qPCR. Statistics: a t test with ΔC t -values, * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the corresponding untreated control sample.
P38 Mapk Inhibitor Sb 202190, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p38 mapk inhibitor sb 202190/product/Merck & Co
Average 90 stars, based on 1 article reviews
p38 mapk inhibitor sb 202190 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


In vitro lipopolysaccharide (LPS) and lipoteichoic acid (LTA) stimulation of neonatal and adult whole blood (WB) in the presence of specific inhibitors. Human WB was preincubated with 20 μ M of the p38 MAPK inhibitor SB202190, 20 μ M of the ERK1/2 inhibitor U0126, 20 μ M of the JNK inhibitor SP600125, or 20 μ M of the NF- κ B inhibitor BAY11-7082, followed by LPS (100 ng/mL) ((a) and (c)) or LTA (100 μ g/mL) ((b) and (d)) for an additional 4 h. Supernatants were then collected, and IL-6 ((a) and (b)) and TNF- α ((c) and (d)) were analyzed using ELISA. Data are presented as fold difference as compared to untreated controls. Values are expressed as mean ± standard error of mean (SEM). * P < 0.05, control versus inhibitor. # P < 0.05, neonatal versus adult.

Journal: Mediators of Inflammation

Article Title: LPS- and LTA-Induced Expression of IL-6 and TNF- α in Neonatal and Adult Blood: Role of MAPKs and NF- κ B

doi: 10.1155/2014/283126

Figure Lengend Snippet: In vitro lipopolysaccharide (LPS) and lipoteichoic acid (LTA) stimulation of neonatal and adult whole blood (WB) in the presence of specific inhibitors. Human WB was preincubated with 20 μ M of the p38 MAPK inhibitor SB202190, 20 μ M of the ERK1/2 inhibitor U0126, 20 μ M of the JNK inhibitor SP600125, or 20 μ M of the NF- κ B inhibitor BAY11-7082, followed by LPS (100 ng/mL) ((a) and (c)) or LTA (100 μ g/mL) ((b) and (d)) for an additional 4 h. Supernatants were then collected, and IL-6 ((a) and (b)) and TNF- α ((c) and (d)) were analyzed using ELISA. Data are presented as fold difference as compared to untreated controls. Values are expressed as mean ± standard error of mean (SEM). * P < 0.05, control versus inhibitor. # P < 0.05, neonatal versus adult.

Article Snippet: In enzyme-linked immunosorbent assay (ELISA) experiments, whole neonatal cord and adult blood samples were incubated with 20 μ M of the NF- κ B inhibitor BAY11-7082 (Merck, Hull, UK), 20 μ M of the p38 MAPK inhibitor SB202190 (Merck), 20 μ M of the ERK1/2 inhibitor U0126 (Enzo Life Sciences, Lörrach, Germany), or 20 μ M of the JNK inhibitor SP600125 (Merck) for 30 min.

Techniques: In Vitro, Enzyme-linked Immunosorbent Assay

Effects on phosphorylated p38 MAPK, ERK1/2, JNK, and NF- κ B in monocytes after stimulation with lipopolysaccharide (LPS) and lipoteichoic acid (LTA) of whole blood (WB) in vitro. WB was stimulated with LPS (100 ng/mL) or LTA (100 μ g/mL) for 15 min. The red blood cells were lysed, and the leukocytes were fixed and permeabilized. The samples were stained with antibodies against CD14 (FITC-conjugated), phosphorylated p38 MAPK (pT180/pY182; Alexa Fluor 647 conjugated), ERK1/2 (pT202/Y204; PE-conjugated), JNK (Thr183/Tyr185; Alexa Fluor 647 conjugated), and/or NF- κ B p65 (pS529; PE labeled) and analyzed for the intracellular levels of phosphorylated signaling proteins based on the determination of MFI by flow cytometry. Stimulated samples were compared with unstimulated controls, and the results were expressed as fold change in phosphorylation: * P < 0.05, LPS or LTA versus control. # P < 0.05, neonatal versus adult.

Journal: Mediators of Inflammation

Article Title: LPS- and LTA-Induced Expression of IL-6 and TNF- α in Neonatal and Adult Blood: Role of MAPKs and NF- κ B

doi: 10.1155/2014/283126

Figure Lengend Snippet: Effects on phosphorylated p38 MAPK, ERK1/2, JNK, and NF- κ B in monocytes after stimulation with lipopolysaccharide (LPS) and lipoteichoic acid (LTA) of whole blood (WB) in vitro. WB was stimulated with LPS (100 ng/mL) or LTA (100 μ g/mL) for 15 min. The red blood cells were lysed, and the leukocytes were fixed and permeabilized. The samples were stained with antibodies against CD14 (FITC-conjugated), phosphorylated p38 MAPK (pT180/pY182; Alexa Fluor 647 conjugated), ERK1/2 (pT202/Y204; PE-conjugated), JNK (Thr183/Tyr185; Alexa Fluor 647 conjugated), and/or NF- κ B p65 (pS529; PE labeled) and analyzed for the intracellular levels of phosphorylated signaling proteins based on the determination of MFI by flow cytometry. Stimulated samples were compared with unstimulated controls, and the results were expressed as fold change in phosphorylation: * P < 0.05, LPS or LTA versus control. # P < 0.05, neonatal versus adult.

Article Snippet: In enzyme-linked immunosorbent assay (ELISA) experiments, whole neonatal cord and adult blood samples were incubated with 20 μ M of the NF- κ B inhibitor BAY11-7082 (Merck, Hull, UK), 20 μ M of the p38 MAPK inhibitor SB202190 (Merck), 20 μ M of the ERK1/2 inhibitor U0126 (Enzo Life Sciences, Lörrach, Germany), or 20 μ M of the JNK inhibitor SP600125 (Merck) for 30 min.

Techniques: In Vitro, Staining, Labeling, Flow Cytometry

(A, B) Calu-3 cells were treated with flagellin (200 ng/ml) in the presence (10 μM) or absence of inhibitors of ERK or p38 MAPK (A), or NF-κB (B) for 24 h. Untreated and DMSO-treated cells served as controls. mRNA expression levels of TMPRSS2 and IL-6 were analyzed at 24 h post-treatment by RT–qPCR. Statistics: a t test with ΔC t -values, * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the corresponding untreated control sample.

Journal: Life Science Alliance

Article Title: Expression of TMPRSS2 is up-regulated by bacterial flagellin, LPS, and Pam3Cys in human airway cells

doi: 10.26508/lsa.202201813

Figure Lengend Snippet: (A, B) Calu-3 cells were treated with flagellin (200 ng/ml) in the presence (10 μM) or absence of inhibitors of ERK or p38 MAPK (A), or NF-κB (B) for 24 h. Untreated and DMSO-treated cells served as controls. mRNA expression levels of TMPRSS2 and IL-6 were analyzed at 24 h post-treatment by RT–qPCR. Statistics: a t test with ΔC t -values, * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the corresponding untreated control sample.

Article Snippet: Treatment with 10 μM ERK inhibitor U0126 monoethanolate (U120; Merck), p38 MAPK inhibitor SB 202190 (S7067; Merck), or NF-κB inhibitor BAY 11-7821 (Merck Millipore) was performed for 1 h before flagellin stimulation.

Techniques: Expressing, Quantitative RT-PCR